Elevated circulating soluble interleukin-2 receptor in patients with chronic liver diseases is associated with non-classical monocytes

BMC Gastroenterology

Frank Tacke²  Christian Trautwein²  Ralf Weiskirchen¹  Henning W Zimmermann²  Sebastian Seidler² 

[1] Institute of Clinical Chemistry and Pathobiochemistry, University Hospital, RWTH-Aachen, Germany;Department of Medicine III, University Hospital, RWTH-Aachen, Germany

关键词: Macrophages;    Monocytes;    CD25;    Interleukin-2;    Liver fibrosis;    Liver cirrhosis;   

Others  :  1113098
DOI  :  10.1186/1471-230X-12-38

 received in 2011-12-28, accepted in 2012-04-24,  发布年份 2012

【 摘 要 】

Background

The soluble interleukin-2 receptor (sIL-2R, sIL2R, sTAC, sCD25) is a reliable biomarker for disease activity in inflammatory disorders such as sarcoidosis. Based on the essential pathogenic role of inflammation for progression of liver diseases, we hypothesized that sIL-2R might be an indicator of inflammatory cell activation and disease severity in patients with chronic liver diseases (CLD).

Methods

We measured sIL-2R serum levels in 71 patients with different stages and etiologies of CLD in comparison to 41 healthy controls. Serum sIL-2R concentrations were correlated with laboratory markers of liver diseases, cytokine / chemokine levels and circulating immune cell subpopulations as simultaneously assessed by FACS analysis from peripheral leukocytes.

Results

CLD patients showed significantly elevated serum sIL-2R levels compared with controls. sIL-2R was significantly higher in patients with compared to patients without established liver cirrhosis and increased with the Child-Pugh stage of cirrhosis, independent of the underlying etiology. sIL-2R levels correlated inversely with parameters indicating the hepatic biosynthetic capacity, such as albumin or international normalized ratio, and positively with non-invasive markers of liver fibrosis such as hyaluronic acid or procollagen-III-peptide. Circulating immune cells might represent a major source of sIL-2R. In fact, sIL2-R levels correlated closely with circulating monocytes, especially non-classical CD14+ CD16+ monocytes, which were found to express high levels of CD25 by FACS. Pro-inflammatory cytokines, including IL-2, IFNγ or IL-6, and chemokines were also associated with sIL2-R. In addition, renal failure was an important confounder of sIL-2R levels independent of liver dysfunction and inflammation.

Conclusions

sIL-2R is elevated in patients with liver diseases and cirrhosis, is associated with circulating inflammatory cells and is increased in concomitant renal failure. These data indicate that sIL-2R might be a potential marker for immune cell activation in CLD, especially for proinflammatory and profibrogenic non-classical CD14 + CD16+ monocytes.

【 授权许可】

   
2012 Seidler et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Rubin LA, Kurman CC, Fritz ME, Biddison WE, Boutin B, Yarchoan R, Nelson DL: Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J Immunol 1985, 135(5):3172-3177.
• [2]Lawrence EC, Brousseau KP, Berger MB, Kurman CC, Marcon L, Nelson DL: Elevated concentrations of soluble interleukin-2 receptors in serum samples and bronchoalveolar lavage fluids in active sarcoidosis. Am Rev Respir Dis 1988, 137(4):759-764.
• [3]Junghans RP, Waldmann TA: Metabolism of Tac (IL2Ralpha): physiology of cell surface shedding and renal catabolism, and suppression of catabolism by antibody binding. J Exp Med 1996, 183(4):1587-1602.
• [4]Semenzato G, Bambara LM, Biasi D, Frigo A, Vinante F, Zuppini B, Trentin L, Feruglio C, Chilosi M, Pizzolo G: Increased serum levels of soluble interleukin-2 receptor in patients with systemic lupus erythematosus and rheumatoid arthritis. J Clin Immunol 1988, 8(6):447-452.
• [5]Bien E, Balcerska A: Serum soluble interleukin 2 receptor alpha in human cancer of adults and children: a review. Biomarkers 2008, 13(1):1-26.
• [6]Witkowska AM: On the role of sIL-2R measurements in rheumatoid arthritis and cancers. Mediators Inflamm 2005, 2005(3):121-130.
• [7]Gillis S, Ferm MM, Ou W, Smith KA: T cell growth factor: parameters of production and a quantitative microassay for activity. J Immunol 1978, 120(6):2027-2032.
• [8]Nelson DL, Rubin LA, Kurman CC, Fritz ME, Boutin B: An analysis of the cellular requirements for the production of soluble interleukin-2 receptors in vitro. J Clin Immunol 1986, 6(2):114-120.
• [9]Minami Y, Kono T, Miyazaki T, Taniguchi T: The IL-2 receptor complex: its structure, function, and target genes. Annu Rev Immunol 1993, 11:245-268.
• [10]Robb RJ, Munck A, Smith KA: T cell growth factor receptors. Quantitation, specificity, and biological relevance. J Exp Med 1981, 154(5):1455-1474.
• [11]Uchiyama T, Broder S, Waldmann TA: A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells. J Immunol 1981, 126(4):1393-1397.
• [12]Waldmann TA: The structure, function, and expression of interleukin-2 receptors on normal and malignant lymphocytes. Science 1986, 232(4751):727-732.
• [13]Anegon I, Cuturi MC, Trinchieri G, Perussia B: Interaction of Fc receptor (CD16) ligands induces transcription of interleukin 2 receptor (CD25) and lymphokine genes and expression of their products in human natural killer cells. J Exp Med 1988, 167(2):452-472.
• [14]Herrmann F, Cannistra SA, Levine H, Griffin JD: Expression of interleukin 2 receptors and binding of interleukin 2 by gamma interferon-induced human leukemic and normal monocytic cells. J Exp Med 1985, 162(3):1111-1116.
• [15]Holter W, Goldman CK, Casabo L, Nelson DL, Greene WC, Waldmann TA: Expression of functional IL 2 receptors by lipopolysaccharide and interferon-gamma stimulated human monocytes. J Immunol 1987, 138(9):2917-2922.
• [16]Loughnan MS, Sanderson CJ, Nossal GJ: Soluble interleukin 2 receptors are released from the cell surface of normal murine B lymphocytes stimulated with interleukin 5. Proc Natl Acad Sci U S A 1988, 85(9):3115-3119.
• [17]Tsudo M, Uchiyama T, Uchino H: Expression of Tac antigen on activated normal human B cells. J Exp Med 1984, 160(2):612-617.
• [18]Robb RJ, Kutny RM: Structure-function relationships for the IL 2-receptor system. IV. Analysis of the sequence and ligand-binding properties of soluble Tac protein. J Immunol 1987, 139(3):855-862.
• [19]Heymann F, Trautwein C, Tacke F: Monocytes and macrophages as cellular targets in liver fibrosis. Inflamm Allergy Drug Targets 2009, 8(4):307-318.
• [20]Tacke F, Luedde T, Trautwein C: Inflammatory pathways in liver homeostasis and liver injury. Clin Rev Allergy Immunol 2009, 36(1):4-12.
• [21]El-Shanawani FM, Abdel-Hadi AA, Abu Zikri NB, Ismail A, El-Ansary M, El-Raai A: Clinical significance of aflatoxin, mutant P53 gene and sIL-2 receptor in liver cirrhosis and hepatocellular carcinoma. J Egypt Soc Parasitol 2006, 36(1):221-239.
• [22]Garcia Ruiz P, Canora Lebrato J, Diez Ruiz A, Fuchs D, Wachter H: Soluble interleukin-2 and tumor necrosis factor receptor in liver cirrhosis. Relationship with clinical severity and prognosis. Med Clin (Barc) 2004, 122(12):441-443.
• [23]Barak V, Selmi C, Schlesinger M, Blank M, Agmon-Levin N, Kalickman I, Gershwin ME, Shoenfeld Y: Serum inflammatory cytokines, complement components, and soluble interleukin 2 receptor in primary biliary cirrhosis. J Autoimmun 2009, 33(3–4):178-182.
• [24]Yamaguchi S, Onji M, Ohta Y: Increased serum soluble interleukin 2 receptor levels in patients with viral liver diseases. Hepatogastroenterology 1988, 35(5):245-248.
• [25]Zimmermann HW, Seidler S, Gassler N, Nattermann J, Luedde T, Trautwein C, Tacke F: Interleukin-8 is activated in patients with chronic liver diseases and associated with hepatic macrophage accumulation in human liver fibrosis. PLoS One 2011, 6(6):e21381.
• [26]Seidler S, Zimmermann HW, Bartneck M, Trautwein C, Tacke F: Age-dependent alterations of monocyte subsets and monocyte-related chemokine pathways in healthy adults. BMC Immunol 2010, 11:30. BioMed Central Full Text
• [27]Zimmermann HW, Seidler S, Nattermann J, Gassler N, Hellerbrand C, Zernecke A, Tischendorf JJ, Luedde T, Weiskirchen R, Trautwein C, et al.: Functional contribution of elevated circulating and hepatic non-classical CD14CD16 monocytes to inflammation and human liver fibrosis. PLoS One 2010, 5(6):e11049.
• [28]Karlmark KR, Zimmermann HW, Roderburg C, Gassler N, Wasmuth HE, Luedde T, Trautwein C, Tacke F: The fractalkine receptor CX3CR1 protects against liver fibrosis by controlling differentiation and survival of infiltrating hepatic monocytes. Hepatology 2010, 52(5):1769-1782.
• [29]Koch A, Voigt S, Kruschinski C, Sanson E, Duckers H, Horn A, Yagmur E, Zimmermann H, Trautwein C, Tacke F: Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients. Crit Care 2011, 15(1):R63. BioMed Central Full Text
• [30]Zimmermann HW, Koch A, Seidler S, Trautwein C, Tacke F: Circulating soluble urokinase plasminogen activator is elevated in patients with chronic liver disease, discriminates stage and aetiology of cirrhosis and predicts prognosis. Liver Int 2012, 32(3):500-509.
• [31]Pizzolo G, Chilosi M, Vinante F, Dazzi F, Lestani M, Perona G, Benedetti F, Todeschini G, Vincenzi C, Trentin L, et al.: Soluble interleukin-2 receptors in the serum of patients with Hodgkin's disease. Br J Cancer 1987, 55(4):427-428.
• [32]Zimmermann HW, Tacke F: Modification of Chemokine Pathways and Immune Cell Infiltration as a Novel Therapeutic Approach in Liver Inflammation and Fibrosis. Inflamm Allergy Drug Targets 2011, 10(6):509-536.
• [33]Colvin RB, Fuller TC, MacKeen L, Kung PC, Ip SH, Cosimi AB: Plasma interleukin 2 receptor levels in renal allograft recipients. Clin Immunol Immunopathol 1987, 43(2):273-276.
• [34]Takamatsu T, Yasuda N, Ohno T, Kanoh T, Uchino H, Fujisawa A: Soluble interleukin-2 receptors in the serum of patients with chronic renal failure. Tohoku J Exp Med 1988, 155(4):343-347.
• [35]Gerbes AL, Gulberg V, Bilzer M, Vogeser M: Evaluation of serum cystatin C concentration as a marker of renal function in patients with cirrhosis of the liver. Gut 2002, 50(1):106-110.
• [36]Karlmark KR, Weiskirchen R, Zimmermann HW, Gassler N, Ginhoux F, Weber C, Merad M, Luedde T, Trautwein C, Tacke F: Hepatic recruitment of the inflammatory Gr1+ monocyte subset upon liver injury promotes hepatic fibrosis. Hepatology 2009, 50(1):261-274.
• [37]Duffield JS, Forbes SJ, Constandinou CM, Clay S, Partolina M, Vuthoori S, Wu S, Lang R, Iredale JP: Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J Clin Invest 2005, 115(1):56-65.